A Retrospective Clinical Study Exploring Prognostic Factors in Esophageal Cancer Patients

Nanfang Hospital, Southern Medical University

Status: Active, not recruiting

Conditions: Esophageal Cancer (EsC)

Treatments: Other: radiotherapy; Procedure: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines; Drug: Immunotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT06960889

NFEC-2025-163

Details and patient eligibility

About

This single-center, retrospective, 7-year observational study aims to investigate prognostic factors in esophageal cancer patients. Adults (≥18 years) with histologically confirmed esophageal cancer who received antitumor therapy between January 2017 and December 2024 were consecutively enrolled. Patient-level data (clinical characteristics, routine laboratory tests, tumor information, and treatment details) were retrospectively collected from electronic medical records to analyze key factors influencing treatment efficacy.

Enrollment: 500 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Waiver of informed consent for deceased or lost-to-follow-up patients (January 2017-March 2024)
2. Voluntary signed informed consent from surviving patients who could be contacted
3. Treatment at Nanfang Hospital, Southern Medical University (January 2017-December 2024)
4. Received antitumor therapy for esophageal cancer
5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2

Exclusion criteria

1. Concurrent other malignancies
2. Patients deemed ineligible by investigators

Trial design

500 participants in 3 patient groups

Radiotherapy Group

Description:

Participants will receive definitive radiotherapy or radiotherapy-based combined modality therapy.

Treatment:

Other: radiotherapy

Immunotherapy Group

Description:

Participants will receive immune checkpoint inhibitors as monotherapy or in combination with other therapies.

Treatment:

Drug: Immunotherapy

Surgery Group

Description:

Participants will undergo radical esophagectomy with or without neoadjuvant/adjuvant therapy.

Treatment:

Procedure: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines